As of April 2025, Dr. Kasner reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Thomas Jefferson University, from the following companies:

• Astellas
• Daiichi Sankyo

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with honoraria:

• Jazz Pharmaceuticals
• Ono Pharmaceuticals 

Teaching in or developing continuing medical education with funding from the following companies, with compensation for travel expenses and honoraria:

• GERON, continuing medical education speaker, without compensation. 

Dr. Lim has been an Assistant Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah since October 2018. She is the recipient of two foundation-sponsored grants to determine the epidemiology and risk factors for inhibitor development in non-severe hemophilia A patients. She has co-authored over 30 peer-reviewed publications.

She is ABIM Board Certified in Hematology and Medical Oncology. Her clinical interest lies in the field of hemostasis and thrombosis. Her research interest is focused on complications affecting patients with congenital bleeding disorders, specifically hemophilia patients with inhibitors.

Dr. Lim earned her medical degree at Cambridge University, England, and completed her two-year foundation training in the United Kingdom. She then completed residency in internal medicine at the Mayo Clinic Rochester and fellowship training in hematology and oncology at the University of North Carolina at Chapel Hill.

As of September 2024, Dr. Lim reported the following external relationships:

Service on a research-related advisory board for the following companies, with compensation for travel expenses and honoraria:  

• BioMarin Pharmaceutical Inc.
• National Hemophilia Foundation
• Sanofi
• Takeda 

Dr. Lim serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

• Hemostasis and Thrombosis Research Society, Education Officer, without compensation. 
   

As of August 2023, Dr. Argote reported no ongoing external relationships.

Dr. Boggio is an Assistant Professor of Medicine in the Department of Medicine, Division of Hematology and Oncology, Section of Hematology at Rush University Medical Center and Clinical Director of the Rush Hemophilia and Thrombophilia Treatment Center, a federally funded comprehensive treatment center for children and adults with hemophilia, Von Willebrand disease and other bleeding disorders, as well as a wide range of clotting disorders. She is also a codirector of the consultative hematology service.

She is a member of the American Society of Hematology, the Hemophilia Foundation of Illinois, the National Hemophilia Foundation, the World Federation of Hemophilia, the International Society on Thrombosis and Haemostasis, the Hemophilia and Thrombosis Research Society, the American Association of Blood Banks, the American College of Physicians, the American Society of Clinical Apheresis and the Hemophilia and Thrombosis Research Society. She has contributed to several committees within these societies. She is also a member of the Hemophilia Foundation of Illinois Board of Directors and Medical Director of Camp Warren Jyrch. She is a guest reviewer for several journals, including The Journal of Thrombosis and Haemostasis, Drugs, Blood Coagulation and Fibrinolysis, The Journal of the American Medical Association, The American Journal of Cardiology and Haemophilia.

Dr. Boggio has expertise in bleeding and thrombotic disorders, cytopenia, myeloproliferative disorders and myelodysplastic disorders. She has authored numerous publications and was a recipient of the David Green-Hau Kwaan Teaching Award at Northwestern University.

Dr. Boggio graduated from Chicago Medical School and completed her residency in internal medicine and a fellowship in hematology and oncology at Northwestern University. She is ABIM Board Certified in Hematology.

As of October 2024, Dr. Boggio reported the following external relationships:

Service on a research-related advisory board for the following companies, with reimbursement for travel expenses and honoraria:  

• Genentech
• Genzyme
• Novo Nordisk
• Octapharma USA
• Sanofi 

Research-related consulting for the following company, with reimbursement for travel expenses and honoraria:  

• CSL Behring 

Dr. Cataldo is an Associate Professor of Clinical Medicine at Louisiana State University Health Sciences Center and Section Chief of Hematology and Medical Oncology of Our Lady of the Lake Physician Group in Baton Rouge, Louisiana. He is ABIM Board Certified in Internal Medicine, Hematology and Medical Oncology. He previously served as a member and later a mentor of the ABIM Hematology Item-Writing Task Force.

Dr. Cataldo received a Bachelor of Science in Zoology from Louisiana State University and his medical degree from Louisiana State University Health Sciences Center in New Orleans. He completed internal medicine residency at Louisiana State University Health Sciences Center (Charity Hospital), and a fellowship in hematology and medical oncology at MD Anderson Cancer Center in Houston, where he served as chief fellow in the final two years of fellowship.

As of October 2024, Dr. Cataldo reported no ongoing external relationships.

Dr. Gertz is the Roland Seidler Jr. Professor of the Art of Medicine and Chair of the Department of Medicine at the Mayo Clinic in Rochester, Minnesota. He is ABIM Board Certified in Internal Medicine, Hematology and Medical Oncology. Previously, Dr. Gertz served as Treasurer for the International Myeloma Society and President of Mayo Staff Officers and Councilors. He also formerly chaired the Mayo Personnel Committee. He is the Chair of the ABIM Hematology Board.

Dr. Gertz has been recognized as a Mayo Distinguished Clinician and in 2014 received the Jan Waldenström Medal for Medical and Scientific Achievements in Waldenström's Macroglobulinemia. He is recognized for contributions in amyloidosis and Waldenström's macroglobulinemia. He has authored more than 500 peer-reviewed publications in the field and is a frequently invited speaker across the country.

Dr. Gertz is a Master of the American College of Physicians. His undergraduate degree was awarded with highest distinction from Northwestern University, where he graduated Phi Beta Kappa. Dr. Gertz received his medical degree cum laude from Loyola University Chicago’s Stritch School of Medicine in Maywood, Illinois, where he was elected to Alpha Omega Alpha, the medical honor society. He completed a three-year medical residency at Rush-Presbyterian-St. Luke’s Medical Center in Chicago where he was twice voted Resident of the Year.

As of September 2024, Dr. Gertz reported the following external relationships:

Research-related consulting for the following companies, receiving reimbursement for travel expenses and honoraria:  

• AbbVie, receiving honoraria.
• Ackea Therapeutics, receiving honoraria.
• Alexion, receiving honoraria.
• Alnylam Pharmaceuticals, receiving honoraria.
• AstraZeneca, receiving honoraria.
• Dava Oncology, receiving honoraria.
• Janssen, receiving honoraria.
• Johnson & Johnson, receiving honoraria.
• Medscape Education, receiving honoraria.
• Prothena, receiving reimbursement for travel expenses.
• Sanofi, receiving honoraria. 

Industry-supported continuing medical education supported by the following, with compensation as listed:

• Alnylam, receiving honoraria.  

Teaching in industry-sponsored satellite symposia with funding from the following company, with compensation as listed:  

• Johnson & Johnson, receiving honoraria.

Dr. Hermosillo Rodriguez is the Area Specialty Chief – Oncology/Hematology for Colorado Permanente Medical Group (CPMG), Franklin Medical Office in Denver. He is ABIM Board Certified in Internal Medicine, Hematology and Medical Oncology.

His areas of focus are cancers of the prostate, bladder and ureter, kidney, lymphoma and leukemia, lung, breast, brain, colorectal and gastrointestinal malignancies, and blood disorders. He also has a special interest in LGBTQ+ care and gender-affirming care.

Dr. Hermosillo Rodriguez received a medical degree from Tecnológico de Monterrey in Mexico. He completed internal medicine residency training and an oncology and hematology fellowship at Baylor College of Medicine in Houston, where he served one year as a chief fellow.

As of November 2024, Dr. Hermosillo Rodriguez reported no ongoing external relationships.

As of May 2025, Dr. Kouides reported the following external relationships:

Service on data and safety monitoring boards for the following company, with honoraria:

• CSL Behring

Dr. Kra is a hematologist/oncologist with Rutgers Cancer Institute of New Jersey and the Division of Hematology/Medical Oncology at Rutgers New Jersey Medical School. He is ABIM Board Certified in Internal Medicine, Hematology and Medical Oncology.

Dr. Kra received a medical degree from the Albert Einstein College of Medicine and completed internal medicine residency training at Mount Sinai Beth Israel in New York City, where he served one year as chief resident. He completed fellowship training in hematology and medical oncology at the Cancer Institute of New Jersey.

As of November 2024, Dr. Kra reported no ongoing external relationships.

Dr. Larson is Professor of Medicine in the Section of Hematology/Oncology and Director of the Hematologic Malignancies Clinical Research Program at the University of Chicago. He is a fellow of the Leukemia Society of America and was granted a Clinical Oncology Career Development Award from the American Cancer Society. He has been a member of the faculty in the Section of Hematology/Oncology and the Comprehensive Cancer Center at the University of Chicago since 1983.

He was Director of the Leukemia Clinical Research Program at the University of Chicago from 1983 to 2000, during which time he established the adult allogeneic bone marrow transplant program at the University of Chicago Medical Center in 1986. He is ABIM Board Certified in Internal Medicine, Hematology and Medical Oncology, and served on the former Subspecialty Board on Hematology and the SEP Committee on Hematology.

Dr. Larson was chair of the Leukemia Committee of the Cancer and Leukemia Group B (CALGB), where he directed a large portfolio of clinical trials and correlative laboratory studies in acute and chronic leukemias. He is currently a member of the National Cancer Institute's Leukemia Steering Committee.

Dr. Larson is a former Councilor on the Executive Committee of the American Society of Hematology and served as the Treasurer of ASH between 2011 and 2014. He was awarded the Henry M. Stratton Medal for Clinical Science in 2019. He has been a faculty member at ASH’s Clinical Research Training Institute, and he has been an invited speaker at the Highlights of ASH in North America, Latin America, Asia and the Mediterranean.

He received his medical degree from the Stanford University School of Medicine and completed his postdoctoral training in internal medicine, hematology and medical oncology at the University of Chicago.

As of September 2024, Dr. Larson reported the following external relationships:

Service on data and safety monitoring boards for the following companies, with honoraria:

• Epizyme, for a Phase II trial of EZH2 inhibitor. 'Takeda, for a Phase III clinical trial of ponatinib in chronic myeloid leukemia. 

Service on a research-related expert panel or advisory board for the following companies, with honoraria:

• CVS
• Novartis 

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with honoraria:

• Daiichi Sankyo
• Novartis 

Dr. Petkova is a hematologist with Houston Methodist Academic Medicine Associates – Hematology and an Assistant Professor of Clinical Medicine in the Academic Institute, Department of Medicine, of Houston Methodist and Weill Cornell Medical College. She provides care at the Houston Methodist Dr. Mary and Ron Neal Cancer Center and is affiliated with Houston Methodist Hospital. She is ABIM Board Certified in Hematology and board certified by the American Board of Pathology in Blood Banking/Transfusion Medicine.

Dr. Petkova received a medical degree from the Medical University of Sofia in Bulgaria. She completed internal medicine residency training at Ascension Illinois and a hematology and oncology fellowship at the Medical College of Wisconsin Associated Hospitals, where she also completed fellowship training in blood banking and transfusion medicine.

As of November 2024, Dr.Petkova reported the following external relationships:

Dr. Williams is the Byrd S. Leavell Professor of Medicine and Professor of Pathology at the University of Virginia (UVA) School of Medicine and an oncologist at the Emily Couric Clinical Cancer Center. He has served in several leadership roles including Chief of the Hematology/Oncology Division. His patient care and research interests include mantle cell lymphoma, other non-Hodgkin lymphomas and CLL, with a focus on targeted agents and immuno-therapeutics. He serves the Scientific Advisory Board of the Lymphoma Research Foundation as an emeritus member. He was honored by the inaugural LRF Mantle Cell Lymphoma Leadership Award in 2021 and by establishment of the Dr. Michael Williams Abstract Achievement Award for MCL Research.

He is a member of the Eastern Cooperative Oncology Group Lymphoma Core Committee and of the European Mantle Cell Lymphoma Network. Dr. Williams is a past chair of the former ABIM Subspecialty Board on Hematology, a past chair of the ABIM Hematology Board and a past member of the ABIM Council, among other volunteer roles. He serves on the editorial boards of The Journal of Clinical Oncology and Annals of Lymphoma, and is Associate Editor for Hematologic Malignancies for The New England Journal Medicine Group Journal Watch Oncology and Hematology. He participates regularly in national and international programs devoted to research and education in lymphoma and CLL.

Dr. Williams received his medical degree from the University of Cincinnati College of Medicine and Master of Science from the Harvard School of Public Health. He completed his medical residency, chief residency and fellowship at UVA Health.

As of April 2025, Dr. Williams reported the following external relationships:

Service on a research-related expert panel or advisory board for the following companies, with honoraria:

• AstraZeneca
• IntrinsiQ Specialty Solutions Inc.
• MJH Life Sciences 

Work as an author or editor for following the company, with compensation as listed:

• The Massachusetts Medical Society, receiving compensation for serving as Associate Editor for Hematologic Malignancies for the NEJM Group (part of the Massachusetts Medical Society) Journal Watch Oncology & Hematology publication. 

Dr. Means, who is ABIM Board Certified in Internal Medicine and Hematology, was the former Dean and presently Professor of Internal Medicine at the James H. Quillen College of Medicine, East Tennessee State University in Johnson City, Tennessee.

Before coming to Quillen, he was Executive Dean of the University of Kentucky College of Medicine. Other positions Dr. Means has held include Senior Associate Chair of Internal Medicine, Interim Director of the Markey Cancer Center and Chief of the Medical Service at the Lexington VA Medical Center. He served as Director of the Hematology Oncology Division at the Medical University of South Carolina and was on faculty at the University of Cincinnati and Vanderbilt.

Dr. Means is a past president of the Southern Society for Clinical Investigation and a fellow of the American College of Physicians. He is also an Associate Editor of The Journal of Investigative Medicine and serves on editorial boards for The American Journal of the Medical Sciences, Blood Research and International Journal of Hematology. He is on the Medical & Scientific Advisory Board of the Iron Disorders Institute.

Dr. Means received his bachelor's degree in biochemistry from Rice University in Houston. He earned his medical degree at Vanderbilt University in Nashville. He trained in internal medicine at Baylor College of Medicine Affiliated Hospitals in Houston before returning to Vanderbilt for a fellowship in hematology.

As of October 2024, Dr. Means reported the following external relationships:

Work as an author or editor for the following companies, with compensation as listed:

• Lippincott Williams Wilkins/Wolters Kluwer, receiving compensation as an editor for Wintrobe’s Clinical Hematology.
• UpToDate, receiving compensation as an author and editor.

Dr. Means serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

• Iron Disorders Institute, Member of the Medical & Scientific Advisory Board, without compensation.

Dr. Davidson is an Assistant Professor of Medicine in the Division of Hematology and Oncology at the University of Virginia (UVA), where she practices hematology at the Emily Couric Clinical Cancer Center. She is ABIM Board Certified in Hematology.

Dr. Davidson specializes in a variety of benign and malignant hematologic diseases, with a focus on cellular hematology. She sees patients with myeloproliferative and myelodysplastic disorders, red cell disorders including sickle cell disease, bone marrow failure syndromes, plasma cell dyscrasias, mast cell disorders and disorders of hemostasis and thrombosis. In addition to clinical practice, Dr. Davidson teaches in the second-year medical student course in hematology and plays an active role in resident and fellowship training at UVA. She previously practiced both hematology and oncology at Associates in Oncology/Hematology in Rockville, Maryland.

From 2015 through present, Dr. Davidson has been named to the list of Best Doctors in America. In 2016, she served on the ABIM Standard-Setting Panel for the Hematology Traditional, 10-Year Maintenance of Certification (MOC) Exam. She has been a member of the American Society of Hematology since 2003.

Dr. Davidson received a biology degree summa cum laude from Georgetown University and her medical degree from Washington University in St. Louis. She completed internship and residency in internal medicine at Beth Israel Deaconess Medical Center in Boston and fellowship training in hematology and oncology at UVA.

As of October 2024, Dr. Davidson reported no ongoing external relationships.

Dr. Donald currently practices at Lourdes Oncology Associates in Lafayette, Louisiana. In 2010, he joined the practice and became Managing Partner in 2014. Additionally, at Our Lady of Lourdes Regional Medical Center, he functions as Medical Director of the Oncology Service Line, a member of the Medical Executive Committee and as a Trustee on the Board of Directors. He is ABIM Board Certified in Internal Medicine, Hematology and Medical Oncology.

Dr. Donald advocates for patients with malignancies and hematologic disorders. He is currently President of the Louisiana Oncology Society. He has been appointed to the Board of Directors of the Community Oncology Alliance. In 2013, he was given the Spirit of Hope Award by the American Cancer Society. The American Society of Hematology (ASH) selected him for its Committee on Practice. He also holds the position of ASH’s alternate delegate to the American Medical Association’s House of Delegates. Since 2012, he has served as the Hematology Representative for Louisiana for the Medicare Carrier Advisory Committee (CAC). He served as Co-Chair of the 2017 Annual CAC meeting at the American Society of Clinical Oncology headquarters and was again selected for that role for the 2018 annual meeting at the ASH headquarters. For the 2017 Annual Meeting of ASH, he served as the clinical designee to the Program Committee.

Dr. Donald graduated magna cum laude from Florida A&M University and received his medical degree from the University of Miami School of Medicine. He completed his internship, residency and fellowship at Tulane University. He served as chief resident and chief fellow there and currently holds the position of Clinical Assistant Professor within Tulane’s Department of Hematology/Oncology.

As of June 2025, Dr. Donald reported the following external relationships:

Dr. Donald serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

• The American Society of Hematology, Councilor in Clinical Practice, without compensation.

Dr. Hexner is a physician scientist with an interest in education and two major research interests in malignant hematology: cellular therapies and hematopoietic stem cell transplantation, and myeloproliferative neoplasms (MPN). Both have a translational focus and align with her clinical roles as Medical Director of the Center for Cellular Immunotherapies and as Director of the University of Pennsylvania MPN program. In MPN, she has designed and executed preclinical studies of Janus kinase (JAK) inhibitors and also used bioassays and correlative studies in MPN patients treated with JAK inhibitors focused on resistance.

Her work in MPN, cellular therapies, stem cell transplantation, primary cell systems and preclinical and clinical investigation allows her to intersect productively with basic science, transfusion medicine, regulatory and clinical colleagues. In another major area of focus. Dr. Hexner serves as the Associate Director of the National Institutes of Health Clinical and Translational Science Awards-funded Masters in Translational Research program at the University of Pennsylvania, serving on the education, selection and curriculum committees and overseeing a cohort of candidates as a programmatic mentor.

Dr. Hexner received her medical degree from Columbia University. She completed her residency at NewYork-Presbyterian/Columbia University Medical Center and her fellowship at the Hospital of the University of Pennsylvania.

As of June 2025, Dr. Hexner reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Pennsylvania, from the following companies:

• DISC Medicine
• Kartos
• National Cancer Institute

Service on data and safety monitoring boards for the following companies, with honoraria:

• Blueprint Medicines
• Sana Biotechnology

Dr. Hexner also reported receiving compensation for reviewing R01 grants for the Food and Drug Administration.

Dr. Leissinger is a Professor of Medicine and Clinical Professor of Pediatrics and Pathology at Tulane University in New Orleans, and Chief of the Hematology/Oncology Division. She became Director of the Louisiana Comprehensive Hemophilia Care Center (now the Louisiana Center for Bleeding and Clotting Disorders) in 1992 and has remained in that position ever since. She is ABIM Board Certified in Internal Medicine and Hematology.

In addition to caring for patients with bleeding and clotting disorders, Dr. Leissinger oversees an active research program. She participates in several clinical research groups and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management.

Dr. Leissinger is actively involved in the American Society of Hematology, the International Society on Thrombosis and Hemostasis, and the Hemostasis and Thrombosis Research Society.

Dr. Leissinger received her medical degree from Tulane University School of Medicine. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at the National Institutes of Health in Bethesda, Maryland, and a clinical fellowship in hematology and medical oncology at Tulane.

As of June 2023, Dr. Leissinger reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to Tulane University, from the following companies:

• Biomarin, for a study of a Factor VIII gene therapy
• Roche, for a study of a new Factor VIII mimetic protein

Service on a research-related expert panel or advisory boards for the following companies, with honoraria:

• CSL Behring
• Pfizer

Service on data and safety monitoring boards for the following company, with honoraria:

• Editas, for a data monitoring committee for gene therapy

Teaching in satellite symposia funded by the following companies, with compensation for travel expenses and honoraria:

• Biomarin, receiving reimbursement for travel expenses and honoraria
• Octapharma, receiving honoraria

Dr. Shafer is the Director for Malignant Hematology Clinical Research at Inova Schar Cancer Institute in Fairfax, Virginia. Previously, she was Assistant Professor in the Division of Hematology, Oncology and Palliative Care at Virginia Commonwealth University. She also served on the former ABIM Hematology Exam Committee and joined the Hematology Traditional, 10-Year MOC Exam Approval Committee in 2023.

Dr. Shafer is ABIM Board Certified in Internal Medicine, Hematology and Medical Oncology. Her clinical interest lies in the treatment of leukemia and lymphoma as well as in clinical trials. Her research interest has been focused on early therapeutics in acute myeloid leukemia.

Dr. Shafer received her medical degree from Chicago College of Osteopathic Medicine. She completed her fellowship at Fox Chase Cancer Center and her residency at Loyola University Medical Center.

As of May 2025, Dr. Shafer reported the no ongoing external relationships.